Assessing outcomes for breast cancer patients
AssigneeMayo Foundation for Medical Education and Research
InventorsMatthew P. Goetz, James N. Ingle, Fergus J. Couch, Matthew M. Ames
Life of this patent
Estimating the term…
Abstract
This document provides methods and materials related to assessing the likely outcome for mammals (e.g., humans) with cancer (e.g., breast cancer). For example, methods and materials for using the ratio of HOXB13 polypeptide expression to IL-17BR polypeptide expression, CYP2D6 genotype, medication history, or combinations thereof to determine the likelihood of a breast cancer patient to experience breast cancer relapse or death are provided.
Claims17
A method for assessing the likelihood of cancer relapse, wherein said method comprises:
- (a) determining whether or not a breast cancer patient contains cancer tissue with a HOXB13:IL17BR expression ratio greater than −1.339 and
- (b) determining whether or not said breast cancer patient contains a CYP2D6*4/WT or a CYP2D6*4/*4 genotype,
- wherein the presence of said HOXB13:IL17BR expression ratio greater than −1.339 or the presence of said genotype indicates that said patient is likely to experience cancer relapse.
A method for assessing the likelihood of cancer survival, wherein said method comprises:
- (a) determining whether or not a breast cancer patient contains cancer tissue with a HOXB13:IL17BR expression ratio less than −1.339 and
- (b) determining whether or not said breast cancer patient contains a CYP2D6*4/WT or a CYP2D6*4/*4 genotype,
- wherein the presence of said HOXB13:IL17BR expression ratio less than −1.339 or the absence of said genotype indicates that said patient is likely to experience longer survival than a comparable breast cancer patient who contains cancer tissue with a HOXB13:IL17BR expression ratio greater than −1.339 or who contains said genotype.
A method for assessing the likelihood of cancer relapse, wherein said method comprises:
- (a) determining whether or not a breast cancer patient taking tamoxifen contains cancer tissue with a HOXB13:IL17BR expression ratio greater than −1.339 and
- (b) determining whether or not said breast cancer patient is taking medication selected from the group consisting of fluoxetine, paroxetine sertraline, cimetidine, amiodarone, doxepin, ticlopidine, and haloperidol, wherein said medication is being taken concurrently with said tamoxifen,
- wherein the presence of said HOXB13:IL17BR expression ratio greater than −1.339 or taking said medication indicates that said patient is likely to experience cancer relapse.
Dependencies are inferred from the claim text.